MUSC Hollings Cancer Center | Strategic Alliance Partners

Hamza Hashmi, MD, discusses a real-world study of the efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma.

William Hawkins, MD, will join MUSC Hollings Cancer Center on January 1, 2024, as deputy director, where he will focus on strengthening translational research, increasing clinical trials across South Carolina and assisting Craig Lockhart, MD, with making clinical operations more efficient.

Jezabel Rodriguez-Blanco, PhD, discusses unmet needs for pediatric patients with relapsed brain tumors, including the need for additional treatment approaches for these patients.

A panel of hematology experts discuss use of steroids in the first-line setting as well as several subsequent-line treatments that have recently received FDA approval for patients with steroid-refractory chronic GVHD, which affects up to 50% of patients.

MUSC Hollings Cancer Center researchers discovered a novel mechanism showing how a certain gene mutation can allow tumors to evade detection by the immune system in colorectal cancer patients.

MUSC Hollings Cancer Center researchers hope to save lives by expanding the Tobacco Treatment Program, first implemented at MUSC Health in 2014, to rural and underserved communities to improve overall patient health, save patients money and reduce the number of premature deaths.

A bench-to-bedside-pioneered lung cancer immunotherapy developed at MUSC Hollings Cancer Center is to be included in one of the largest lung cancer clinical trials being offered by the National Cancer Institute.

A new project led by researchers at MUSC Hollings Cancer Center could significantly decrease the side effects associated with CAR-T-cell therapy and make the treatment available to more patients who could benefit.

MUSC Hollings Cancer Center researchers received a grant from the Department of Defense to investigate how dietary fat affects the development of colon cancer and to find more effective methods of treatment.

Carolyn D. Britten, MD, chief, Division of Hematology Oncology, associate director, Clinical Investigations, at the Hollings Cancer Center, Medical University of South Carolina, discusses questions that remain in immunotherapy.

Britten continues as Associate Director for Clinical Investigations for the MUSC Hollings Cancer Center.

International genome-­wide association study (GWAS) also identifies key gene responsible for expressing subtype of ovarian cancer.

New England Journal of Medicine Publishes Study Co-Led by Hollings Cancer Center Researcher Showing Potential of New Genomic Test In Lung Screening.

Dr. Matthew J. Carpenter, an associate professor at the Medical University of South Carolina and researcher with the MUSC Hollings Cancer Center, is the recipient of the 2015 Governor's Young Scientist Award for Excellence in Scientific Research.

Most oncologists do not regularly provide evidence-based tobacco cessation support for patients with cancer who smoke. However, addressing tobacco use is not as difficult as some might think.

Increasing the minimum age of legal access (MLA) to tobacco products will prevent or delay initiation of tobacco use by adolescents and young adults, particularly those ages 15 to 17, and improve the health of Americans across the lifespan.

OncLive today welcomes the Medical University of South Carolina's Hollings Cancer Center as a partner in promoting the latest advances in cancer research, treatment and care through OncLive's Strategic Alliance Partnership program.